Marksans Pharma Limited

Nitin Agarwal

DAM Capital Advisors Ltd

25.7%

art to the year with a solid growth in the first quarter across our regions. Our US region grew by 25.7%, while UK and Europe grew by 13.7% driven by a strong volume growth and new product launches. Pric

13.7%

in the first quarter across our regions. Our US region grew by 25.7%, while UK and Europe grew by 13.7% driven by a strong volume growth and new product launches. Pricing erosion continued to be high in

38%

ng our generic business. However, our RoW revenue doubled, while Australia and New Zealand grew by 38%. The inflationary headwind continued in the quarter with the increase in cost of material and frei

4%

th momentum and hopefully improve our profitability. We obviously aim to increase our R&D spend to 4% to 5% of sales over the coming years. Our low-cost manufacturing capabilities provide us with a co

5%

entum and hopefully improve our profitability. We obviously aim to increase our R&D spend to 4% to 5% of sales over the coming years. Our low-cost manufacturing capabilities provide us with a competit

INR 433.8 crore

Thank you, Sir. I will explain the financial performance of Q1 FY22-23. Operating revenue was at INR 433.8 crore, increase of 24.3% compared with INR 349 crore last year. US and North America was at INR 173.9 cr

24.3%

ain the financial performance of Q1 FY22-23. Operating revenue was at INR 433.8 crore, increase of 24.3% compared with INR 349 crore last year. US and North America was at INR 173.9 crores and witnessed

INR 349 crore

rformance of Q1 FY22-23. Operating revenue was at INR 433.8 crore, increase of 24.3% compared with INR 349 crore last year. US and North America was at INR 173.9 crores and witnessed 25.7% growth YoY. EU and UK

INR 173.9 crore

433.8 crore, increase of 24.3% compared with INR 349 crore last year. US and North America was at INR 173.9 crores and witnessed 25.7% growth YoY. EU and UK formulations market recorded 13.7% growth standing at I

INR 181crore

es and witnessed 25.7% growth YoY. EU and UK formulations market recorded 13.7% growth standing at INR 181crores. Australia and New Zealand formulation market recorded 37.8% growth at INR 52.6 crores. Whereas t

37.8%

rded 13.7% growth standing at INR 181crores. Australia and New Zealand formulation market recorded 37.8% growth at INR 52.6 crores. Whereas the Rest of World recorded 99% increase in the sales to INR 26.

INR 52.6 crore

h standing at INR 181crores. Australia and New Zealand formulation market recorded 37.8% growth at INR 52.6 crores. Whereas the Rest of World recorded 99% increase in the sales to INR 26.3 crores in Q1 FY23. Gros